Dementia with Lewy bodies (DLB), the second most common type of dementia, requires a multifactorial approach to reduce symptoms.

The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s ...

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a ...

The trial failed to achieve statistical significance in its goal of improved MCCB neurocognitive composite scores.

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active ...

A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...

VINE senior center has received a $10,000 grant from the Mankato Clinic Foundation to support four new programs designed to ...

Loxapine may be effective for the treatment of schizophrenia but does not differ greatly from the older typical antipsychotics (chlorpromazine, trifluperazine, perphenazine) or other atypicals ...

Acute extrapyramidal side effects after using metoclopramide are harmless and reversible, but undoubtedly a dramatic and unpleasant experience for patients. It is essential to be aware that the ...

Dementia with Lewy bodies (DLB), the second most common type of dementia, requires a multifactorial approach to reduce symptoms.